The rare disease opportunity in China: Large patient pools, faster identification and growing engagement
One of the greatest challenges in rare disease clinical research is not developing innovative therapies. It is finding the right patients.
Across the world, rare disease sponsors must navigate fragmented healthcare systems, delayed diagnoses and small patient populations. These challenges can extend recruitment timelines and increase development costs.
China is beginning to change that equation.
With one of the largest, rare disease populations globally and an increasingly connected healthcare ecosystem, China offers unique opportunities for patient identification, recruitment and long-term engagement.
Why is patient recruitment challenging in rare disease trials?
Recruitment remains a primary obstacle in rare disease studies. Patients are often distributed across wide geographic areas and many spend years seeking an accurate diagnosis. Historically, this challenge was also significant in China. However, ongoing investments in rare disease infrastructure have created new pathways for identifying patients more efficiently and connecting them with appropriate care. These developments are helping create a more organized environment for clinical research.
How does China support rare disease identification?
One of the most important developments has been the creation of a national rare disease hospital network. The network now includes 419 hospitals and supports referrals, telemedicine consultations and clinical data sharing.1 These capabilities help patients reach specialized care more quickly while allowing clinicians across regions to collaborate more effectively. The efforts to make care more accessible help to reduce time to diagnosis and lower overall healthcare costs.
For clinical trial sponsors, this increased connectivity can support more efficient patient identification and access to specialized treatment centers.
How digital innovation is improving patient identification
Technology is becoming an increasingly important component of rare disease care in China. The China Alliance for Rare Diseases has established digital health capabilities that support diagnosis, patient management, clinical research and drug development activities. These tools help connect stakeholders across the healthcare ecosystem while creating opportunities to improve patient journeys.2
Artificial intelligence is also beginning to play a role. PUMCH-GENESIS, a large language AI model developed through collaboration between Peking Union Medical College Hospital and the Chinese Academy of Sciences, is designed specifically to support more accurate and efficient rare disease diagnosis using extensive clinical and genetic datasets.3
For sponsors, improvements in diagnosis can have a direct impact on clinical development by increasing the likelihood that eligible patients are identified earlier.
The growing influence of patient communities
Patient organizations are another important component of China's rare disease ecosystem. Many rare disease communities have formed volunteer-led advocacy groups that maintain close connections with major treatment centers. These organizations often provide education, support and awareness resources for patients and families navigating complex medical conditions.
They can also help facilitate communication between patients, healthcare professionals and researchers. As patient engagement continues to grow, these communities are becoming an increasingly valuable source of insight into patient needs and treatment experiences.
Expanding access to rare disease care
China has continued to expand its official list of recognized rare diseases, which now includes 207 conditions. In addition, more than 90 rare disease drugs have been included within the national medical insurance framework. These developments are helping reduce financial barriers and improve access to treatment.4
Greater awareness and improved access can contribute to stronger patient engagement with healthcare systems and potentially increase participation in clinical research.
How can global sponsors benefit from China's rare disease ecosystem?
For organizations developing therapies for rare diseases, China offers more than simply a large patient population.
The country is building an increasingly connected ecosystem that combines hospital networks, digital health platforms, patient communities and advanced diagnostic technologies. Together, these factors support a more efficient approach to identifying and engaging patients living with rare conditions.
As rare disease studies become more specialized and competition for eligible participants increases, access to well-connected patient populations may become one of the most important considerations in global development planning.
China's scale remains important. However, the real story may be the growing sophistication of the systems that connect patients, clinicians and researchers.
Learn more about how Fortrea can support your rare disease study.